Organigram Announces Proposed Acquisition of Sanity Group, a Leading German Cannabis Company

Executive Summary

• Organigram Global Inc. entered a definitive agreement to acquire all outstanding shares of Berlin‑based Sanity Group GmbH for an upfront €113.4 million (≈ C$183.7 M) plus up to €113.8 million in earnout consideration tied to post‑closing performance.
• The transaction will be financed through cash on hand, a new senior secured credit facility (up to US$60 M), and a C$65.2 M private placement investment from British American Tobacco (BAT).
• The acquisition is positioned as financially accretive, expanding Organigram’s footprint into Europe’s two largest federally legal cannabis markets (Canada and Germany) and providing a vertically integrated “hub” for higher‑margin flower sales.

Key Details

• Purchase Price:
• Upfront cash €80 M (≈ C$129.6 M).
• Upfront share consideration €33.4 M (≈ C$54.1 M) at C$3.00 per Organigram share – a 71% premium to the TSX closing price on Feb 17, 2026.

• Earnout up to €113.8 M (first €20 M cash, remainder in shares priced at the 20‑day VWAP with a C$3.00 floor / C$4.00 cap).

• Financing Sources:

• Cash on hand (restricted Jupiter funds).
• Private placement investment from BAT: subscription for 14,027,074 Organigram common shares at C$3.00 (gross proceeds C$42.08 M) plus exercise of top‑up rights for 9,897,356 shares at C$2.335854 (gross proceeds C$23.12 M).

• Senior secured credit facility with ATB Financial: up to US$60 M (US$40 M revolving/operating line + US$20 M non‑revolving term loan).

• Earnout Mechanics:

• Based on a notional “Sanity Valuation” weighting net revenue (×1.75) and EBITDA (×12.5), each 50% of the calculation, capped at €250 M inclusive of Organigram interests.

• Maximum total consideration (upfront + earnout) €227.2 M (≈ C$405 M).

• Working Capital Support:

• Up to €10 M available to Sanity on closing; any unrepaid amount reduces the earnout payout.

• Closing Timeline & Conditions:

• Expected Q2 2026 concurrent close of acquisition, private placement, and credit facility.

• Subject to regulatory approvals (TSX, German foreign‑direct investment clearance), shareholder approval (≥50.1% of non‑BAT votes) and customary closing conditions.

• Strategic Rationale:

• Provides Organigram with a European hub, access to Germany’s fast‑growing medical cannabis market (valued > €2 B in 2025, projected > €4.5 B by 2028).
• Adds two legal specialty retail locations in Switzerland and positions Organigram for expansion into the UK, Poland, and Czechia.

• Expected to be financially accretive; Sanity generated positive EBITDA in 2025 and shows strong margin improvement (gross margin up from 15% in 2023 to 47% in 2025).

• Governance & Approvals:

• Board of Directors approved the transaction after receiving a fairness opinion from BMO Capital Markets.
• BAT, an insider holder, will abstain from voting on the acquisition.

Notable Quotes

• “The proposed acquisition of Sanity Group marks a pivotal step in Organigram's global expansion strategy… extending our commercial footprint into Europe.” – James Yamanaka, CEO, Organigram.
• “Sanity’s strong focus in Europe is highly complementary to Organigram’s strengths… together we are poised to unlock significant growth opportunities.” – Finn Age Hänsel, CEO, Sanity Group.

Materiality Assessment: Material – Positive (the deal materially expands Organigram’s geographic reach, adds a high‑growth European platform, and is expected to be accretive to revenue and earnings).